Stay Informed on Corporate Sustainability

Author: Pharmaphorum

Roche is fast-tracking a new antibiotic, zosurabalpin, into phase 3 trials to combat carbapenem-resistant Acinetobacter baumannii—a hospital-acquired ‘superbug’ the CDC calls an urgent threat.

Author: Nordic Life Science

Hansa Biopharma is set to cut 20% of its workforce as part of a sweeping restructure aimed at streamlining operations and sharpening its focus.

Author: Pharmaceutical Technology

As pricing pressures and political headwinds reshape the pharma landscape, Genentech is doubling down on American manufacturing.

Author: Pharmaphorum

Despite market volatility, regulatory unknowns, and geopolitical headwinds, Europe’s life sciences sector is seeing sustained VC confidence.

Author: Biopharma Diver

Sanofi is doubling down on neuroscience with a $470 million acquisition of Vigil Neuroscience, securing full rights to an early-stage Alzheimer’s drug targeting the immune-linked protein TREM2.

Author: Pharmaceutical Technology

Merck KGaA is advancing its CSF-1R inhibitor pimicotinib toward global approval after a Phase III trial in TGCT patients delivered promising efficacy and functional outcomes.

Author: PMLive

BioNTech is betting big on British science, committing up to £1bn over the next decade to expand its regional R&D footprint.

Author: News-Medical

For pharma leaders chasing faster discovery and scale, manual colony picking has long been a bottleneck, slow, error-prone, and resource-intensive.

Author: PMLive

Regeneron is set to acquire the core assets of 23andMe for $256 million, absorbing its genome services, biobank, and research operations following the latter’s bankruptcy proceedings.

Author: April Lara

Peak Technologies helps you streamline production, reduce errors, and stay ahead with intelligent MES solutions.